-- Mary Elizabeth Dallas
TUESDAY, June 3, 2014 (HealthDay News) -- Researchers working
with mice have identified a drug they believe holds promise as a
preventive treatment for Alzheimer's disease.
In the study, the compound cut levels of amyloid beta -- a
protein associated with this degenerative brain disease -- by about
half, the researchers said.
Years before Alzheimer's develops, amyloid beta starts to build
up and clump in the brain. Scientists believe that helping the
brain remove this protein in late middle age might ward off the
Preventing Alzheimer's may be more feasible than stopping it
once it develops and damages the brain, the NYU Langone Medical
Center researchers said.
"The key is to prevent the disease process from going that far," said the study's leader, Dr. Martin Sadowski, associate professor of neurology, psychiatry, and biochemistry and molecular pharmacology.
A treatment based on this compound, known as 2-PMAP, might
thwart Alzheimer's, the researchers said. They found that the
compound enters the brain easily and specifically targets amyloid
proteins, reducing the risk for certain side effects. Since it is
non-toxic for mice, they suspect it is likely safe enough to be
taken regularly by people over a long period of time.
"What we want in an Alzheimer's preventive is a drug that modestly lowers amyloid beta and is also safe for long-term use," Sadowski said in an NYU news release.
"Statin drugs that lower cholesterol appear to have those properties and have made a big impact in preventing coronary artery disease. That's essentially what many of us envision for the future of Alzheimer's medicine," he added.
However, results achieved in animal studies aren't necessarily
duplicated in humans.
In conducting the study, published online June 3 in
Annals of Neurology, the researchers screened a collection
of compounds and found that 2-PMAP dramatically reduced the
production of amyloid precursor protein -- the "mother protein" of
amyloid beta. In test cells, this lowered amyloid beta levels by 50
percent or more.
The mice involved in the research were engineered to have the
same genetic mutations as people with a hereditary form of
Alzheimer's disease. After receiving a five-day treatment with
2-PMAP, the levels of amyloid precursor protein and amyloid beta in
brains of the mice dropped dramatically.
Treatment over four months appeared to prevent the mental
deficits usually seen in these mice as they get older, according to
the news release.
The researchers said they are now working on ways to make 2-PMAP
Alzheimer's is currently the most common form of dementia,
affecting more than 5 million Americans. Prevalence of the disease
is expected to triple by 2050 if effective preventive treatments
are not developed.
The U.S. National Institute on Aging provides more information
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.